Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.33
-0.1100-4.51%
Post-market: 2.330.00000.00%16:10 EDT
Volume:751.11K
Turnover:1.75M
Market Cap:279.60M
PE:-2.21
High:2.45
Open:2.42
Low:2.28
Close:2.44
52wk High:3.23
52wk Low:0.9401
Shares:120.00M
Float Shares:104.94M
Volume Ratio:0.75
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.82
PE(LYR):-2.03

Loading ...

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Sector Update: Healthcare

MT Newswires Live
·
Jul 10

Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839

MT Newswires Live
·
Jul 10

Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed

TIPRANKS
·
Jul 09

Fate Therapeutics Wins FDA IND Clearance for Dual-target CAR-T Candidate FT839

Reuters
·
Jul 09

Fate Therapeutics - Enrollment in Phase 1/2 Study of FT839 Expected to Begin in H2 2026

THOMSON REUTERS
·
Jul 09

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

THOMSON REUTERS
·
Jul 09

Fate Therapeutics - FT839 Trial to Initially Target Rheumatoid Arthritis, Vasculitis, Myositis, Lupus, Systemic Sclerosis

THOMSON REUTERS
·
Jul 09

Fate Therapeutics - FT819 Also Being Evaluated in Sle; Phase 2 Trial Planned in Lupus Nephritis

THOMSON REUTERS
·
Jul 06

Fate Therapeutics Reports Preliminary FT819 CAR-T Data Showing Skin Score Improvement in Systemic Sclerosis Patients

Reuters
·
Jul 06

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

GlobeNewswire
·
Jul 02

H.C. Wainwright Reaffirms Their Buy Rating on Fate Therapeutics (FATE)

TIPRANKS
·
Jun 24

Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities

TIPRANKS
·
Jun 22

Fate Therapeutics Shareholders Back Directors and Governance Plans

TIPRANKS
·
Jun 16

Fate Therapeutics shareholders approve 7 million-share increase to equity incentive plan

Reuters
·
Jun 16

BRIEF-Fate Therapeutics Appoints Laura Hamill To Board Of Directors

Reuters
·
Jun 15

Fate Therapeutics appoints former Gilead commercial chief Laura Hamill to board

Reuters
·
Jun 15

Press Release: Fate Therapeutics Appoints Laura Hamill to Board of Directors

Dow Jones
·
Jun 15

Piper Sandler Remains a Buy on Fate Therapeutics (FATE)

TIPRANKS
·
Jun 09

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 08